AZ Taps Outsider Soriot As CEO, While Roche Anoints 25-Year Veteran O'Day To Head Pharma Division

AstraZeneca has appointed an experienced biotech and pharmaceuticals executive, Pascal Soriot, to its vacant CEO position, while Roche switches Daniel O'Day from its diagnostics to its pharmaceuticals division.

With the appointment of outsider and Frenchman Pascal Soriot to the CEO hot seat at AstraZeneca PLC, the troubled U.K. multinational is gaining an executive experienced in managing the merger of biotechs with multinationals.

This experience might well come in useful over the coming months, with regard to both old and new acquisitions. AstraZeneca’s Gaithersburg, Md.-based subsidiary, MedImmune LLC, is perceived as not yet having delivered on its promise after AstraZeneca spent $15

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Europe

More from Geography

Most Favored Nation Policy ‘Lazy, Misguided,’ But US Price Reforms Politically ‘Inevitable’

 
• By 

Policy experts and pharma executives react to President Trump’s executive order on “equalizing” drug prices between the US and comparable nations at the ISPOR 2025 conference.

Few Takers For EMA’s OPEN Pathway Prompts Rethink

 
• By 

While drug companies say they support the European Medicines Agency’s expanded OPEN framework for the collaborative assessment of marketing applications with non-EU authorities, they are reluctant to participate in the initiative for a number of reasons.

EU Council Could Adopt Pharma Reform Package Next Week, But Disputes Risk A Year’s Delay

 

The Council of the EU wants to adopt its negotiating position on the reform of the general pharmaceutical legislation “sooner, rather than later,” but divergence between member states could push negotiations back another year, a European Commission policy officer said today.